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ABSTRACT
BACKGROUNDANDPURPOSE: Delayed cerebral ischemia and vasospasm are signiﬁcant complications following SAH leading to cerebral
infarction, functional disability, and death. In recent years, CTA and CTP have been used to increase the detection of delayed cerebral
ischemia and vasospasm. Our aim was to perform comparative-effectiveness and cost-effectiveness analyses evaluating CTA and CTP for
delayed cerebral ischemia and vasospasm in aneurysmal SAH from a health care payer perspective.
MATERIALS AND METHODS: We developed a decision model comparing CTA and CTP with transcranial Doppler sonography for
detection of vasospasm and delayed cerebral ischemia in SAH. The clinical pathways were based on the “Guidelines for the Management
of Aneurysmal Subarachnoid Hemorrhage: A Guideline for Healthcare Professionals from the American Heart Association/American
Stroke Association” (2012). Outcome health states represented mortality and morbidity according to functional outcomes. Input proba-
bilities of symptoms and serial test results from CTA and CTP, transcranial Doppler ultrasound, and digital subtraction angiography were
directly derived from an SAH cohort by using amultinomial logistic regressionmodel. Expected beneﬁts, measured as quality-adjusted life
years, and costs, measured in 2012 US dollars, were calculated for each imaging strategy. Univariable, multivariable, and probabilistic
sensitivity analyses were performed to determine the independent and combined effect of input parameter uncertainty.
RESULTS: The transcranial Doppler ultrasound strategy yielded 13.62 quality-adjusted life years at a cost of $154,719. The CTA and CTP
strategy generated 13.89 quality-adjusted life years at a cost of $147,097, resulting in a gain of 0.27 quality-adjusted life years and cost
savings of $7622 over the transcranial Doppler ultrasound strategy. Univariable and multivariable sensitivity analyses indicated that results
were robust to plausible input parameter uncertainty. Probabilistic sensitivity analysis results yielded 96.8% of iterations in the right lower
quadrant, representing higher beneﬁts and lower costs.
CONCLUSIONS: Our model results suggest that CTA and CTP are the preferred imaging strategy in SAH, compared with transcranial
Doppler ultrasound, leading to improved clinical outcomes and lower health care costs.
ABBREVIATIONS: CTAP CTA and CTP; DCI delayed cerebral ischemia; ISAT International Subarachnoid Aneurysm Trial; QALY quality-adjusted life year;
TCD transcranial Doppler ultrasound; WTP willingness to pay
Aneurysmal SAH is a devastating condition resulting in poorclinical outcomes of patients who survive long enough to be
admitted, with approximately 15%mortality and 58% functional
disability.1 Additionally, as many as 20% of survivors have global
cognitive impairment, also contributing to poor functional sta-
tus.2 Thus, SAH is associated with a substantial burden on health
care resources, most of which are related to long-term care.3 De-
spite advances in techniques for aneurysm repair, poor outcomes
remain in SAH partly due to delayed diagnosis and treatment of
its secondary complications, mainly vasospasm and delayed cere-
bral ischemia (DCI).
Currently, there are severalmethods available to assist with the
diagnosis of vasospasm and DCI, including clinical examination,
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neurologic monitoring devices, transcranial Doppler sonography
(TCD), CTA and CTP (CTAP), MR diffusion and perfusion im-
aging, and digital subtraction angiography. In clinical practice,
patients with SAH are primarily assessed by clinical examination
and TCD, with clinical examination limited because symptoms
are variable and difficult to detect4 and TCD limited by poor
sensitivity and specificity.5-7 At the same time, there are studies
reported in the literature that support the use of CTAP for detec-
tion of both vasospasm and perfusion deficits thought to occur in
DCI because of the high sensitivity and specificity of CTAP.8-11
Additionally, emerging data indicate that perfusion imaging may
bemore accurate for identification ofDCI than anatomic imaging
of arterial narrowing or changes in blood flow velocity by
TCD.8,12 Yet, according to the most recent “Guidelines for the
Management of Aneurysmal Subarachnoid Hemorrhage: A
Guideline for Healthcare Professionals from the American Heart
Association/American Stroke Association” (2012),13 both TCD
and perfusion imaging with CT or MR imaging have been as-
signed the same class IIa recommendation and level B evidence
for detection of vasospasm and DCI. Although CTAP has poten-
tial to add important diagnostic information for guidingmanage-
ment and treatment decisions, there are no studies to date, to our
knowledge, that have assessed the added value of CTAPon clinical
outcomes to fully understand its impact in this patient popula-
tion. Furthermore, there have been no randomized trials compar-
ing the impact of different diagnostic methods on patient out-
comes in SAH.
In the past several years, demonstrating the value of imaging
has become a major focus in our changing health care environ-
ment. Both quality and safety advocates and third-party payers
have raised concerns regarding medical practice patterns with in-
appropriate use of CT, particularly as it relates to radiation expo-
sure. It has become particularly important to substantiate imag-
ing for specific clinical conditionswith scientific evidence to guide
management and treatment decisions. The purpose of this study
was to perform comparative effectiveness and cost-effectiveness
analyses evaluating imaging strategies in SAH for detection of
vasospasm and DCI by using evidence-based guidelines from a
health care payer perspective. Our hypothesis was that CTAP is a
cost-effective approach, despite higher imaging costs, compared
with the standard imaging strategy using TCD, resulting in im-




Wedeveloped a decisionmodel to perform comparative effective-
ness and cost-effectiveness analyses by using a decision analytic
framework in the TreeAge software program (TreeAge Pro Soft-
ware, Williamstown, Massachusetts) to compare imaging strate-
gies in SAH from a health care payer perspective. The detailed
model structure is provided in On-line Fig 1. CTAP was consid-
ered the “new imaging strategy” and was compared with TCD as
the “standard imaging strategy.” Clinical examination was in-
cluded in themodel beforeCTAPorTCD imaging to assess symp-
toms of vasospasm and/or DCI, as would typically occur in the
clinical setting. The model was designed to assess patients during
the typical time point at which vasospasm and DCI occur, be-
tween 4 and 14 days after SAH.
In the standard strategy, positive concordance between the
clinical examination and TCD results led to induced hypertensive
therapy, and negative concordance of the clinical examination
and TCD led to observation, whereas discordance between the
clinical examination andTCD results (such as symptoms but neg-
ative TCD findings or no symptoms but positive TCD findings)
led to further testing withDSA. In the new strategy, CTA andCTP
were evaluated as a single examination termed CTAP because
these examinations are typically performed concurrently in clin-
ical practice. If a patient was symptomatic, a positive CTAP find-
ingwas defined as a positive result on either CTAorCTP, whereas
a negative CTAP finding was defined as a negative result on both
CTA and CTP. The rationale is that given the presence of symp-
toms, a positive result on either examination provides sufficient
supportive evidence to prompt treatment decisions. If a patient
was asymptomatic, a positive CTAP finding was defined as a pos-
itive result on both CTA and CTP, whereas a negative CTAP find-
ing was defined as a negative result on either CTA or CTP. The
rationale is that in the absence of symptoms, a single positive
result on either examination does not provide sufficient evidence
to prompt treatment decisions. All management and treatment
decisions are based on the clinical examination andTCDorCTAP
combination tests.
The subsequent management and treatment decisions in the
clinical pathway incorporated in the model were based on the
most recent recommendations in the “Guidelines for theManage-
ment of Aneurysmal Subarachnoid Hemorrhage: A Guideline for
Healthcare Professionals from the American Heart Association/
American Stroke Association” (2012).13 Oral nimodipine was ad-
ministered to all patients with aneurysmal subarachnoid hemor-
rhage (class I recommendation, level A evidence) because it has
been shown to improve neurologic outcomes after SAH. Treat-
ment of DCI is recommended with induction of hypertension
(class I recommendation, level B evidence) and cerebral angio-
plasty and/or selective intra-arterial vasodilator therapy in symp-
tomatic patients, particularly those who are not rapidly respond-
ing to hypertensive therapy (class IIa recommendation, level B
evidence).
Each clinical pathway terminated in an outcome health state
reflecting the downstreammorbidity andmortality. A patient was
assigned to only 1 of the 3 following health states: recovered, dis-
ability with dependence, or death. The long-term complications
of testing or treatment affecting mortality and morbidity (as de-
fined by the health states) were included in themodel. Short-term
complications such as mild allergic reactions were not included
because patients recovered from these temporary ailments; this
outcome would not imply significant reductions in quality of life
contributing to these health states.
Input Parameter Probabilities
Anoutcomes-based approachwas used in developing the decision
model to directly assess the effectiveness of CTAP compared with
TCD on clinical outcomes instead of primarily modeling the op-
erating characteristics of these imaging examinations. We mod-
eled probabilities of test results combined with distributions
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across clinical outcomes, both determined conditional on the
clinical examination and imaging results. The probabilities as-
signed for the occurrence of symptoms and test results of CTAP,
TCD, and DSA were directly derived from an SAH cohort en-
rolled in a diagnostic accuracy study.10 In this cohort, patients had
both CTAP and TCD performed, which allowed direct compari-
son of these imaging strategies in the same patients. According to
the study protocol, CTAP was performed at days 6–8 in asymp-
tomatic patients and the same day that symptoms occurred in
symptomatic patients with clinical deterioration. Day 7 was the
median day CTAP was performed, at which time 45% (44/97) of
patients had developed evidence of clinical deterioration.10 Clin-
ical deterioration may manifest by alterations in consciousness,
worsening on the Glasgow Coma Scale, or new neurologic defi-
cits. For patients with limited clinical examinations, particularly
patients who are comatose or mechanically ventilated, continu-
ous monitoring of laboratory data and neurologic and systemic
parameters was used. The details of the CTP scanning protocol
and postprocessing methods are provided in the On-line Appen-
dix. TCD was performed daily at the patient’s bedside with com-
parisons betweenTCD examinations to evaluate changes in blood
flow velocity measurements.
Clinical outcomes of functional disability were also assessed in
the same SAH cohort10 and obtained frommedical record review
by a neurologist blinded to the hospitalization course and imaging
data. Outcomes were based on the modified Rankin Scale and
were categorized into 3 main health states as recovered (mRS
0–2), disability with dependence (mRS 3–5), and death (mRS 6).
A multinomial prediction model, incorporating conditional de-
pendence of serial imagingwithCTAP andDSAorTCDandDSA,
was developed and fitted to determine the predictive probabilities
for each outcome based on the test results and on being symptom-
atic or asymptomatic. The 95%simultaneous confidence intervals
for predictive probabilities were computed by using an asymp-
totic multivariate normal theory and were based on 2 tests.14
Statistical analysis was performed with “R: A Language and Envi-
ronment for Statistical Computing” (Version 2.13.0;
http://www.r-project.org/).15
Literature sources were used to determine the probabilities of
long-term complications from testing (CTAP and DSA) and/or
treatment with induced hypertension and intra-arterial (IA) ther-
apy. On-line Table 1 demonstrates these input probabilities and
their literature sources.
Assessment of Health Beneﬁts and Costs
Health benefits were measured in quality-adjusted life years
(QALYs). For each health state, we assigned aQALY score ranging
between 0 and 1.0. Lifetime QALYs were calculated by multiply-
ing the sum of the number of years spent in each health state by
the utility associated with that state. The life expectancies were
estimated from the literature as 28 years for “recovered”16,17 and
10.8 years for “disability.”18,19 The utilities were calculated as a
weighted average from a systematic review of utilities assigned
according to mRS scores.20 The utility of “recovered” (mRS 0–2)
was 0.80, and it was 0.22 for “disability” (mRS 3–5). By conven-
tion, “death” (mRS 6) was assigned a value of zero for both life
years and utility.
The economic costs included in the model were those associ-
ated with imaging from CTAP, TCD, and DSA; treatment with
induced hypertension and IA-therapy; complications from imag-
ing and treatment; and disability after SAH, including both short-
and long-term care. The costs for the imaging and treatment were
based on the 2012Medicare reimbursement rates, including both
technical and professional fees. The costs for long-term care for
patients with stroke have been reported in the literature.21 The
estimated cost for recovered patients was calculated as the cumu-
lative annual cost for the expected life years in this health state.
The estimated cost for the disability patients was calculated as the
first-year rehabilitation costs added to the cumulative annual cost
for the remaining expected life years in this health state. By con-
vention, death was assigned no additional cost.
Benefits and costs were discounted at a rate of 3% per year as
recommended for cost-effectiveness analyses in the United
States.22,23
Model Validation
Internal validity (sometimes referred to as model verification)
examines the extent to which the model calculations produced
expected outcomes based on the data that were used to derive the
model inputs.24 We assessed the internal validity of the model by
comparing the predicted probabilities of the health states (recov-
ered, disability, and death) for each imaging strategy in the deci-
sionmodel with the observed outcome data from the SAH cohort.
The percentage difference for the model results compared with
the observed outcomes was calculated as a measure of deviation
for the probabilities of each health state for the standard and new
imaging strategies separately.
External validity is performed in a similar fashion but uses
outcome data that were not used to develop the model as bench-
marks for the predictive performance of the model.24 To evaluate
external validity of the decision model, we compared the overall
predicted probabilities of the health states for both imaging strat-
egies from the decision model with the published outcome prob-
abilities from the International Subarachnoid Aneurysm Trial
(ISAT).1 The percentage difference was also calculated as a mea-
sure of deviation formodel results relative to published outcomes.
Cost-Effectiveness and Sensitivity Analyses
Wecalculated the expected benefits and costs associatedwith each
imaging strategy from the perspective of the health care payer. In
the primary analysis for policy decision-making, the symptomatic
and asymptomatic subgroups were combined in each imaging
strategy, weighted by the frequency of symptoms. Additional sub-
group analyses were performed to compare the symptomatic and
asymptomatic groups separately. An imaging strategy that yielded
the greatest quality-adjusted life years and lowest costs would be
considered the imaging strategy of choice (dominant strategy).
Sensitivity analyses were performed to test the robustness of
the results of the model, given the uncertainty in the input values
for the parameters. One-way sensitivity analyses were performed
for each parameter by altering the input values across the entire
range of possible values (0–1) to identify the key drivers of the
model results. In addition, 2-way sensitivity analyses were per-
formed by simultaneously altering the input values for 2 param-
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eters together to assess their combined effects on the results of the
model. A willingness-to-pay (WTP) threshold of $100,000 per
QALY was used in the 1-way and 2-way sensitivity analyses.
Probabilistic sensitivity analysis was performed to assess the
uncertainty in themodel results, incorporating the uncertainty of
all parameter values together. Distributions for the key model
parameters were derived by nonparametric bootstrapping of the
SAH cohort,25 focusing attention on the probability of symptoms
and the probabilities of imaging (CTAP, TCD, and DSA) condi-
tional on symptoms. Nonparametric bootstrapping was per-
formed by resampling analytic datasets with replacement to eval-
uate the precision around point estimates without making
assumptions regarding the distribution of these variables.26 Pa-
rameters that were not directly derived from the cohort (n 97),
such as all other probability inputs, costs, and utilities, were as-
signed distributions (such as, uniform, and ) and varied on the
basis of the SD estimates around themean values. distribution is
a flexible one, which is bounded by 0 and 1, whichmakes it useful
for varying probability inputs in probabilistic sensitivity analy-
sis.26 Uniform distributions assume equal probability of possible
random values between 0 and 1.26  distributions are rightward
skewed with a lower bound at zero, which makes them useful for
varying cost inputs in probabilistic sensitivity analysis.26 On-line
Table 1 demonstrates the input values and distributions used for
all parameters in the model. Results of the probabilistic analysis
(10,000 iterations) were used to generate a cost-effective scatter-
plot and cost-effectiveness acceptability curves to demonstrate
the probability that the new strategy is cost-effective for varying
cost per QALY thresholds.
RESULTS
Input Parameter Probabilities
On-line Table 1 demonstrates the probabilities of positive and nega-
tive test results for CTAP, TCD, and DSA in symptomatic and
asymptomatic patients calculated directly from the SAH cohort10
and the predictive probabilities of the outcome health states derived
from the multinomial prediction model, incorporating serial imag-
ing and clinical data with conditional dependence.
Model Validation Results
The internal validation revealed that the deviations in the overall
probabilities of patients with good (recovered) and poor (disabil-
ity and death) outcomes estimated from the decision model for
the new strategy were 1.2% and 3.4%, respectively, relative to the
observed data from the SAH cohort. Within the poor-outcomes
group, deviations in the probabilities for disability and deathwere
0.9% and 13.7%, respectively. For the standard strategy, the devi-
ations in the overall probabilities of patients with good and poor
outcomes estimated from the decision model were 5.4% and
16.7%, respectively.Within the poor-outcomes group, deviations
in the probabilities for disability and death were 20% and 3.8%,
respectively.
The external validation revealed that
the deviations in the overall probabilities
of patients with good and poor outcomes
derived from the decision model were
1.4% and 3.0%, respectively, compared
with the published outcomesdata fromthe
ISAT.1 Within the poor-outcomes group,
deviations in the probabilities for disability
and death were 55.3% and 62.2%,
respectively.
Base Case Analysis
The Table demonstrates the health bene-
fits (QALYs) and costs for the base case
scenario and the subgroup analyses in the
symptomatic and asymptomatic patients
separately. CTAP resulted in a gain of
health benefits with a cost savings in all
analyses, thereby dominating the stan-
dard imaging strategy.
Sensitivity Analysis
Univariable (1-way) sensitivity analyses
indicated that the study results were ro-
FIG 1. Multivariable (2-way) sensitivity analysis graph demonstrating how the decision depends
on the values of the probability of positive ﬁndings on a CTA and CTP examination in symp-
tomatic patients (Sx) and the probability of symptoms in the SAH population across all ranges.
The new strategy represents CTAP imaging, and the standard strategy represents TCD imaging.
Health beneﬁts (QALYs) and costs for the base case scenario and
subgroup analyses in symptomatic and asymptomatic patients












Difference (CTAP-TCD) 0.48 $11,044
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bust to plausible uncertainty in the parameter values. The CTAP
strategy remained preferred (assuming a WTP of $100,000 per
QALY) for all parameters varied over the full range of possible
input values, except for the following: 1) the probability of posi-
tive CTAP fell below 44.2% in symptomatic patients; 2) the prob-
ability of complications from induced hypertension rose above
20.5%; and 3) the probability of recovery with negative CTAP
findings fell below 51.1% in symptomatic and 85.9% in asymp-
tomatic patients. Multivariable (2-way) sensitivity analyses using
the probability of positiveCTAP findings in symptomatic patients
and the probability of symptoms revealed that the CTAP strategy
is dominant when the probability of positive CTAP findings in
symptomatic patients is75% (Fig 1).
The results of the probabilistic sensi-
tivity analysis (10,000 iterations) were
used to generate a cost-effectiveness scat-
terplot (Fig 2A) and cost-effectiveness ac-
ceptability curves (Fig 2B). The cost-ef-
fectiveness scatterplot shows that 96.8%
of the iterations in the probabilistic sensi-
tivity analysis lie in the right lower quad-
rant, representing higher effectiveness
and lower costs. The cost-effectiveness ac-
ceptability curves show that the probabil-
ity that the new strategy is cost-effective is
consistently high for varying cost per
QALY thresholds. At the WTP of $50,000
and $100,000 per QALY, the probabilities
that the CTAP strategy is preferred are
98.5% and 98.0%, respectively.
DISCUSSION
Our study reveals that performing CTAP
in patients with SAH improves clinical
outcomes compared with TCD, with in-
creased quality of life from less functional
disability. Although CTAP is associated
with higher upfront imaging and treat-
ment costs, there are substantial cost sav-
ings associated with this imaging strategy
due to overall decreased costs spent on
long-term care for patients with func-
tional disability. Our 1-way and probabi-
listic sensitivity analyses assessed a range
of costs for CTAP, from $0 to $2000, and
revealed that across these different
thresholds, CTAP is still the preferred
strategy compared with TCD. CTAP rep-
resents a dominant strategy because it
provides both better health outcomes and
lower costs in the overall patient popula-
tion and in the symptomatic and asymp-
tomatic subgroups separately. These
results support the implementation of
CTAP in all SAH, including both symp-
tomatic and asymptomatic patients. Fur-
thermore, our study demonstrates that
changing the WTP threshold from
$50,000 to $100,000 does not significantly change the model re-
sults. The cost-effective acceptability curves generated from the
probabilistic sensitivity analysis are helpful in visualizing the ef-
fect that a change inWTP can have on these results (Fig 2). CTAP
remains the preferred imaging strategy across the entire range of
commonly used WTP thresholds in the United States.27
In this cost-effectiveness analysis, an outcomes-based ap-
proach was used to directly assess the effectiveness of CTAP com-
pared with TCD on clinical outcomes. Most decision analyses for
diagnostic tests model the underlying diagnostic truth in combi-
nation with the sensitivity and specificity of the test.27 Here we
modeled probabilities of test results combined with distributions
across clinical outcomes, both determined conditional on the
FIG 2. Probabilistic sensitivity analysis scatterplot (A) and cost-effectiveness acceptability
curves (B) comparing the new strategy versus the standard strategy. The new strategy repre-
sents CTAP imaging and the standard strategy represents TCD imaging.
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clinical examination and previous test results. We chose this al-
ternative approach because of controversy about the appropriate
reference standard test for DCI and lack of diagnostic perfor-
mance data of these tests. Because all conditional probabilities of
test results and distributions across clinical outcomes were de-
rived from one and the same well-documented cohort of patients
with SAH,10 this alternative modeling approach ensures internal
consistency of the model. We are confident that the model struc-
ture accurately reflects SAH disease pathways because the model
resultsmatched the health states (good and poor outcomes) com-
pared with the SAH cohort and ISAT populations in our internal
and externalmodel validation analyses. Additionally, the sensitiv-
ity analyses demonstrated that the model results were robust to
variations in the input values for all parameters.
There are several limitations of our study. First, we modeled
health outcomes conditional on diagnostic tests performed in a
single cohort, calling into question the generalizability of the
model. This approach had the advantage of direct comparison of
CTAP and TCD in the same patients, and ensured internal con-
sistency of the data. Even though the external validation of the
model revealed that the proportion of patients with good (recov-
ered) and poor (disability and death) outcomes were similar to
those in the ISAT,1 greater variation was seen within the poor-
outcomes group. The ISAT reported higher mortality compared
with the decisionmodel; this would be expected because the older
data presented in the ISAT (1994–2002) do not adequately reflect
the currently improved mortality rates due to more aggressive
management of complications related to SAH such as hydroceph-
alus, vasospasm, and DCI.13 Additionally, the ISAT reported a
5-year mortality rate rather than the mortality rate within the
hospitalization period that we report, which likely also contrib-
uted to its higher mortality compared with the decision model
because some of our patients may experience delayed mortality
due to stroke complications. Furthermore, deviation in the inter-
nal validation results was also seen in the poor-outcomes group
with the model predicting higher disability and death compared
with the SAH cohort. This deviation in the results may be partly
attributed to the real-world variation in clinical decision making
observed in the SAHcohort comparedwith the decisionmodel, in
which standardized management and treatment decisions were
based strictly on the clinical examination and imaging results.
Second, the potential long-term effects from low-level radiation
exposure used inmedical imaging, such as cancer induction, were
not included in the model because cancer risks at low doses are
very uncertain in the adult population anddepend on limited data
extrapolating risks from atomic bomb survivors who were ex-
posed to high doses.28Currently, there are nodata available on the
lifetime cancer risk from CTAP imaging according to patient age
at exposure, sex, and reduced life expectancy from underlying
disease, particularly aneurysmal subarachnoid hemorrhage, de-
layed cerebral ischemia, and/or vasospasm. Because our model
was designed to specifically assess patients during the typical time
point of DCI and vasospasm between days 4 and 14 after SAH, we
only included themorbidity andmortality during the hospitaliza-
tion period and at discharge. Last, the possible added benefits of
performing serial TCD examinations at the bedside to improve
detection of vasospasm by monitoring temporal changes in
blood-velocity measurements and avoiding intrahospital trans-
portationwere not included in the decision analysis because of the
lack of estimates in the literature to accurately incorporate them
in the model.
CONCLUSIONS
In summary, our results have important implications in clinical
practice in managing patients with SAH. Ourmodel suggests that
CTAP is the preferred initial imaging strategy compared with
TCD because it results in both improved clinical outcomes and
lower health care costs. Furthermore, the results of this study
provide supportive evidence for the widespread implementation
of CTAP in both symptomatic and asymptomatic patients. In the
current economic environment aimed at improving health care
quality and reducing costs, imaging patients with SAHwithCTAP
should achieve both aims.
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